UCB SA (OTCMKTS:UCBJY) Short Interest Down 73.8% in June

UCB SA (OTCMKTS:UCBJY) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 5,769 shares, a drop of 73.8% from the June 15th total of 21,989 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 70,017 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

UCBJY has been the topic of several recent analyst reports. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Monday, June 22nd. Finally, Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Stock Down 4.8%

OTCMKTS:UCBJY traded down $6.83 during trading hours on Friday, reaching $135.91. 23,360 shares of the stock were exchanged, compared to its average volume of 27,183. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average of $144.02 and a two-hundred day moving average of $147.99. UCB has a twelve month low of $98.24 and a twelve month high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.